Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan (Prostate Cancer and Prostatic Diseases, (2022), 10.1038/s41391-022-00555-0)

In this article, author names Yu-Hsuan Joni Shao, Jian-Hua Hong, Chun-Kai Chen, and Chao-Yuan Huang were incorrectly written as Shao Yu-Hsuan Joni, Hong Jian-Hua, Chen Chun-Kai, and Huang Chao-Yuan. Tables 1 and 2 have been adjusted to reflect consistency within the paper. They now show as seen below.Risk groups defined by National Comprehensive Cancer Network guidelines were as follows: Low risk: T1–T2a, GS ≤ 6, and PSA of 10 ng/mL; favorable intermediate risk: T2b–T2c or GS ≤7 or PSA of 10–20 ng/mL and a primary GS of 3; unfavorable intermediate risk: T2c or GS ≤7 or PSA of 10–20 ng/mL and primary GS of 4; high risk: T3a or GS of 8–10 or PSA >20 ng/mL; very high risk for locally advanced prostate cancer: T3b–T4 or primary GS component scores of ≥5 scores with overall GS of 8–10; metastatic risk: N1 or M1 with any T stage [29]. CCI Charlson comorbidity index, CVD cardiovascular disease(s), GnRH gonadotropin-releasing hormone, PSA prostate specific antigen, TNM where T=tumor, N=nodes and M=metastasis. aYes: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.In the sentence beginning with “Risk groups defined by National Comprehensive Cancer Network...” value “20 ng/ml” has been changed to “>20 ng/mL”. In this article and insertion to the caption to Fig 1 has been made. In the sentence beginning with “Survival curves...” it now reads as “Survival curves showing MACE-free survival probability (significance of difference tested by log rank test)...”. The original article has been corrected.